Real‐World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database
Haemophilia · 2026-07 · 32 (4) · 989-1001
DOI: 10.1111/hae.70313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 21.05.2026. Verfasst von Víctor Jiménez Yuste und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario La Paz-IdiPaz, Servicio de Hematología, Autonoma University, Madrid, Spain. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Health Care AG, Novo Nordisk.
Abstract (Originalsprache)
Introduction
Prophylactic factor replacement and non‐factor therapy has improved bleed prevention and clinical outcomes for people with haemophilia (PwH). The remaining burdens faced by PwH in real‐world settings, despite availability of newer therapies, are not well documented.
Aim
We aimed to describe the haemophilia patient population, assess clinical and humanistic burden of disease, and identify unmest needs associated with current treatments.
Methods
Data were drawn from the Adelphi Real World Haemophilia Disease Specific Programme, a cross‐sectional survey of haemophilia‐treating physicians, their patients with haemophilia A (HA) or B (HB), and caregivers. Data were collected in multiple countries from July 2023 to October 2024. Physicians reported patient demographics, disease characteristics, treatment details, bleeding episodes and joint health status. Patients and caregivers reported health‐related quality of life (HRQoL). Analyses were descriptive.
Results
Overall, 283 physicians reported on 2227 patients, with 67% of PwH aged 18–49 years. Prophylactic compliance was high: 94% of patients were either fairly or fully compliant (taking 50%–80% or >80% of prescribed dose, respectively). However, physicians were not completely satisfied with prophylaxis for 56% of patients with HA and 59% with HB, citing concerns about administration methods, dosing schedules, and efficacy. Joint problems were experienced by 49% of patients; 57% reported ≥1 bleed annually despite prophylaxis. HRQoL impairment was reported by patients on all types of prophylaxis.
Conclusion
Despite current treatment, many PwH continue to experience limitations to their daily activities, productivity, and physical independence. A patient‐centred approach is needed to ensure clinical effectiveness can be balanced with lifestyle priorities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital Universitario La Paz-IdiPaz, Servicio de Hematología, Autonoma University, Madrid, Spain.
- Novo Nordisk Health Care AG, Zürich, Switzerland.
- Novo Nordisk Service Centre India Private Limited, Bangalore, India.
- Adelphi Real World, Bollington, UK.
- Center For Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
Förderung
- Novo Nordisk Health Care AG
- Novo Nordisk
Zitieren
APA
Yuste, V. J., Percier, C., Prashanth, S., Ball, N., Morton, E., & Castaman, G. (2026). Real‐World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database. Haemophilia, 32(4), 989-1001. https://doi.org/10.1111/hae.70313
Vancouver
Yuste VJ, Percier C, Prashanth S, Ball N, Morton E, Castaman G. Real‐World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database. Haemophilia. 2026;32(4):989-1001. doi:10.1111/hae.70313
BibTeX
@article{Yuste2026,
author = {Yuste, Víctor Jiménez and Percier, Cléa and Prashanth, Shwetha and Ball, Nathan and Morton, Ella and Castaman, Giancarlo},
title = {Real‐World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database},
journal = {Haemophilia},
year = {2026},
volume = {32},
number = {4},
pages = {989--1001},
doi = {10.1111/hae.70313}
}
EUVIMED